Hosted on MSN2mon
Denali Therapeutics’ ALS therapy fails to meet primary endpoint in Phase II/III trialIts primary endpoints were to assess changes in disease severity over time using the ALS Functional Rating Scale-Revised, as well as survival rates up to week 24. The trial's secondary endpoints ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback